Post-marketing data: Infections and Infestations: Very rare: Opportunistic infection.
Immune System Disorders: Very rare: Local Hypersensitivity.
Endocrine Disorders: Very rare: Hypothalamic-pituitary-adrenal (HPA) axis suppression: Cushingoid features: (e.g. moon face, central obesity), delayed weight gain/growth retardation in children, osteoporosis, glaucoma, hyperglycaemia/glucosuria, cataract, hypertension, increased weight/obesity, decreased endogenous cortisol levels, alopecia, trichorrhexis.
Eye Disorders: Very rare: Cataract, central serous chorioretinopathy, glaucoma.
Skin and Subcutaneous Tissue Disorders: Common: Pruritus, local skin burning/skin pain. Uncommon: Skin atrophy*, striae*, telangiectasias*. Very rare: Skin thinning*, skin wrinkling*, skin dryness*, pigmentation changes*, hypertrichosis, exacerbation of underlying symptoms, allergic contact dermatitis/dermatitis, pustular psoriasis, erythema, rash, urticaria, acne.
General Disorders and Administration Site Conditions: Very rare: Application site irritation/pain.
*Skin features secondary to local and/or systemic effects of hypothalamic-pituitary-adrenal (HPA) axis suppression.
View ADR Monitoring Form